NEWS

The BUR-EB project has published a new collection of educational materials on EB, now available in Spanish, English, Italian, French, Hungarian, Bulgarian, and German.

Reintroducing DEBRA Greece, the “Greek Association of Epidermolysis Bullosa Patients and their Friends,” a non-profit organization dedicated to supporting individuals and families affected by EB in Greece.

DEBRA International attended EWMA 2026 in Bremen, co-hosting a round table session on EB with DEBRA Germany, sharing clinical and lived experience.

With the publication of the congress supplement in einstein (São Paulo), the effort from EB Congress 2026 has now been captured in a lasting, accessible format.

EB was brought to the heart of European decision-making during a dedicated event at the European Parliament for Rare Disease Day 2026.

Dr Ritu Jain, President of DEBRA International, featured in RARE Revolution Magazine discussing rare disease diagnosis and equitable global care.

EB Congress 2026 in São Paulo united 520 participants from 35+ countries, highlighting DEBRA International sessions, lived experiences, research, and global collaboration in EB care.

In April 2025, EB advocates from all over the world came to Prague to participate in the GlobalSkin conference. We sat with them and listened to their story....

Krystal Biotech’s Vyjuvek has been approved by Japan’s Ministry of Health, Labour and Welfare for the treatment of wounds caused by dystrophic epidermolysis bullosa (DEB). It is the first genetic therapy authorised in Japan for DEB.